Vaccine makers settle France's H1N1 bill

A newspaper has reported that France has struck a deal to pay several large vaccine makers just 16 percent of the amount it had contracted to pay after canceling a huge order of swine flu vaccine. According to Le Figaro, Novartis, GlaxoSmithKline and Sanofi will get €48 million in payment for €358 million of vaccine that the country had ordered and then cancelled. GSK will face the steepest loss from the cancellation. A number of European countries were stuck with large supplies of H1N1 vaccine after the pandemic turned out to be milder than anticipated and a huge portion of their populations shunned the jab. Report

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.